1. Ko JH, Joo EJ, Kim SH, Kim YJ, Huh K, Cho SY, et al. Clinical application of rapid diagnostic test kit for SARS-CoV-2 antibodies into the field of patient care. J Microbiol Immunol Infect. 2021; 54(1):97–100. PMID:
32684340.
Article
2. Ko JH, Joo EJ, Baek JY, Huh K, Cho SY, Kang CI, et al. Evaluation of six anti-SARS-CoV-2 antibody test kits and practical approaches to optimize the diagnostic performance. J Microbiol Immunol Infect. 2021; 54(5):983–986. PMID:
33836943.
Article
3. Lee B, Ko JH, Park J, Moon HW, Baek JY, Jung S, et al. Estimating the neutralizing effect and titer correlation of semi-quantitative anti-SARS-CoV-2 antibody immunoassays. Front Cell Infect Microbiol. 2022; 12:822599. PMID:
35493733.
Article
4. Ko JH, Lee JY, Kim HA, Kang SJ, Baek JY, Park SJ, et al. Serologic evaluation of healthcare workers caring for COVID-19 patients in the Republic of Korea. Front Microbiol. 2020; 11:587613. PMID:
33329460.
Article
5. Yang J, Ko JH, Baek JY, Hong J, Ha S, Lee B, et al. Effects of short-term corticosteroid use on reactogenicity and immunogenicity of the first dose of ChAdOx1 nCoV-19 vaccine. Front Immunol. 2021; 12:744206. PMID:
34630425.
Article
6. Ko JH, Joo EJ, Park SJ, Baek JY, Kim WD, Jee J, et al. Neutralizing antibody production in asymptomatic and mild COVID-19 patients, in comparison with pneumonic COVID-19 patients. J Clin Med. 2020; 9(7):2268. PMID:
32708872.
Article
7. Lee B, Ko JH, Lee KH, Kim YC, Song YG, Park YS, et al. Estimation of SARS-CoV-2 neutralizing activity and protective immunity in different vaccine types using three surrogate virus neutralization test assays and two semiquantitative binding assays targeting the receptor-binding domain. Microbiol Spectr. 2022; 10(6):e0266922. PMID:
36250875.
Article
8. Bae S, Ko JH, Choi JY, Park WJ, Lim SY, Ahn JY, et al. Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity. Clin Microbiol Infect. 2022; 28(10):1390.e1–1390.e7.
Article
10. Yang J, Won G, Baek JY, Lee YH, Kim H, Huh K, et al. Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections. Front Immunol. 2023; 14:1139980. PMID:
36936968.
Article
11. Johnson BA, Zhou Y, Lokugamage KG, Vu MN, Bopp N, Crocquet-Valdes PA, et al. Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis. PLoS Pathog. 2022; 18(6):e1010627. PMID:
35728038.
Article
12. Wang P, Liu L, Nair MS, Yin MT, Luo Y, Wang Q, et al. SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. Emerg Microbes Infect. 2020; 9(1):2091–2093. PMID:
32930052.
Article
13. Yang L, Xu Q, Yang B, Li J, Dong R, Da J, et al. IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients. BMC Microbiol. 2021; 21(1):351. PMID:
34922455.
Article
14. Song SH, Chung KY, Jee Y, Chung HS, Kim K, Minn D, et al. Immunogenicity of SARS-CoV-2 vaccine in kidney transplant recipients: a cross-sectional study in Korea. J Korean Med Sci. 2023; 38(5):e22. PMID:
36747360.
Article
15. Oh YJ, Kim J, Kang ES, Rhu J, Choi GS, Joh JW. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients: a single-center study. J Korean Med Sci. 2023; 38(16):e121. PMID:
37096307.
Article
16. Le Bert N, Tan AT, Kunasegaran K, Tham CY, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584(7821):457–462. PMID:
32668444.
Article
17. Alfego D, Sullivan A, Poirier B, Williams J, Adcock D, Letovsky S. A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States. EClinicalMedicine. 2021; 36:100902. PMID:
34056568.
Article
18. Krutikov M, Palmer T, Tut G, Fuller C, Azmi B, Giddings R, et al. Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England. Lancet Healthy Longev. 2022; 3(1):e13–e21. PMID:
34935001.
Article
19. Van Elslande J, Oyaert M, Ailliet S, Van Ranst M, Lorent N, Vande Weygaerde Y, et al. Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection. J Clin Virol. 2021; 136:104765. PMID:
33636554.
Article